United States - English - NLM (National Library of Medicine)

bryant ranch prepack - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane tablets can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits cause

New Zealand - English - Medsafe (Medicines Safety Authority)

alchemy health limited - exemestane 25mg - film coated tablet - 25 mg - active: exemestane 25mg excipient: colloidal silicon dioxide crospovidone hypromellose   macrogol 400 macrogol 6000 magnesium stearate mannitol microcrystalline cellulose polysorbate 80 purified talc sodium starch glycolate titanium dioxide - exemestane is indicated for: · the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer · the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy · the third-line hormonal treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease progressed following treatment with anti-oestrogens and either non-steroidal aromatase inhibitors or progestins.

Singapore - English - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - exemestane - tablet, film coated - exemestane 25 mg

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)] . exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2) ]. exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemetane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increase

Israel - English - Ministry of Health

inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: sandoz philippines corporation; distributor: n/a - exemestane - film-coated tablet - 25 mg

Philippines - English - FDA (Food And Drug Administration)

singapore genebio, inc.; distributor: endure medical, inc. - exemestane - film-coated tablet - 25 mg

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2) ]. exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemetane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

accord healthcare limited, united kingdom - exemestane - film-coated tablet - 25 mg

Philippines - English - FDA (Food And Drug Administration)

accord healthcare limited - philippine branch office - exemestane - film coated tablet - 25mg